SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jonathan Schonsheck who wrote (2261)4/3/1997 4:47:00 PM
From: Hank   of 4342
 
Jonathan,

I wouldn't expect that AndroCar would be useful in targeting the protein kinase that is implicated in breast cancer. While it inhibits kinases associated with prostrate cancer, the two forms of kinase are undoubtedly different. If AndroCar has a true specificity for prostrate cancer kinases then it shouldn't inhibit ANY other kinases. However,if the molecular details of how AndroCar inhibits kinases in prostrate cancer were know, then perhaps this interaction could be used as a model to design compounds which inhibit kinases associated with other forms of cancer. That would take more money than PRLN currently has though. As for it's lack of side effects, I'm sure that will prove to be a huge plus in it's favor.

Hank
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News